
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc is experiencing a notable increase in projected enterprise value, rising from $2.30 billion to $3.21 billion, which is driven by the anticipated revenue generation from its lead product, deramiocel, in the treatment of Duchenne muscular dystrophy (DMD). The company's innovative therapies show promising clinical outcomes, including a significant 3.3% improvement in left ventricular ejection fraction (LVEF) among patients with cardiomyopathy, suggesting strong market potential and addressing critical unmet medical needs. Additionally, the ongoing development of its proprietary StealthXTM platform enhances its therapeutic offerings in the biotech space, further contributing to a positive outlook for the company’s future financial performance.
Bears say
Capricor Therapeutics Inc faces significant financial challenges that could hinder its growth prospects, including a slower-than-expected market ramp and the potential need for additional equity or debt financing at unfavorable terms, which may lead to dilution. The market potential for the company’s primary product, Deramiocel, may not meet initial projections, raising concerns regarding revenue generation and overall valuation. Furthermore, key risks such as the possibility of failed clinical trials and the inability to secure sufficient funding to advance its therapeutic developments further exacerbate the company’s bleak financial outlook.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares